CUBIST PHARM (CBST) |
Consensus Forecast of CUBIST PHARM Revenue in Millions  |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
11/07 |
| $294.62 |
$433.64 |
$562.14 |
$648.83 |
$736.44 |
25.7% |
|
| Consensus Forecast of CUBIST PHARM EPS |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| ($0.60) |
$0.09 |
$0.85 |
$1.70 |
$1.43 |
$1.62 |
$1.90 |
$2.01 |
|
| Discussion | |
| Last edited Mon May 02, 2011 06:36 AM
by gourabdas (Individual Investor) |  |
EPS FORECASTS
|
This section is designed to find errors as the consensus forecast of EPS. The consensus forecasts for the lines in the CUBIST PHARM Income Statement are shown and below each consensus forecast is a wiki section to discuss why the consensus forecast of that item may be high or low
|
|
| Consensus Forecasts of Total Revenue |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
12/05 |
| 1. Total Revenue |
$120.7 |
$194.8 |
$294.6 |
$433.6 |
$562.1 |
$648.8 |
$736.4 |
$818.8 |
31.5% |
|
| Discussion by Wiki Users | | For FY11, the company upped its total revenues projection to $686 million- $706 million from $680 million-$700 million assuming that Dificid to be launched in the US in August 2011. Cubist has an agreement with Optimer Pharmaceuticals regarding Dificid, which was approved in the US in May 2011.
| Last edited Fri Jun 24, 2011 04:42 AM
by gourabdas (Individual Investor) | |
| Consensus Forecasts of Fully Diluted Shares Outstanding |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| Fully Diluted Shares Outstanding |
53.1 |
55.9 |
68.8 |
68.0 |
67.2 |
68.2 |
69.4 |
71.6 |
|
| Discussion by Wiki Users | |
| Last edited Fri May 14, 2010 02:33 AM
by SudiptaMukherjee (Zacks Investment Research) | |
| Consensus Forecasts of Cost of Goods Sold |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 2. Cost of Goods Sold |
$32.7 |
$48.8 |
$68.9 |
$90.3 |
$116.9 |
$141.5 |
$161.3 |
$180.2 |
| Percent of Revenue |
27% |
25% |
23% |
21% |
21% |
22% |
22% |
22% |
| 3. Gross Profit (1-2) |
$88.00 |
$146.00 |
$225.70 |
$343.30 |
$445.20 |
$507.30 |
$575.10 |
$638.60 |
| Percent of Revenue |
73% |
75% |
77% |
79% |
79% |
78% |
78% |
78% |
|
| Consensus Forecasts of Selling, General and Administrative Expense |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 4. Selling, General and Administrative Expense |
$61.9 |
$83.6 |
$98.7 |
$125.5 |
$136.9 |
$153.8 |
$170.6 |
$186.9 |
| Percent of Revenue |
51% |
43% |
34% |
29% |
24% |
24% |
23% |
23% |
|
| Discussion by Wiki Users | |
| Last edited Mon May 02, 2011 06:38 AM
by gourabdas (Individual Investor) | |
| Consensus Forecasts of Research and Development |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 5. Research and Development |
$51.7 |
$57.4 |
$84.3 |
$125.2 |
$170.6 |
$173.3 |
$196.2 |
$216.9 |
| Percent of Revenue |
43% |
29% |
29% |
29% |
30% |
27% |
27% |
26% |
|
| Discussion by Wiki Users | |
| Last edited Mon May 02, 2011 06:39 AM
by gourabdas (Individual Investor) | |
| Consensus Forecasts of Pre - Tax Income |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 7. Pre - Tax Income |
($31.9) |
$5.3 |
$72.2 |
$97.2 |
$171.5 |
$175.9 |
$218.8 |
$186.0 |
| Net Income |
($31.9) |
$14.5 |
$72.1 |
$106.7 |
$152.7 |
$145.5 |
$160.4 |
$163.7 |
|
| CBST (CUBIST PHARM) |
$585.00 |
$92.26 |
21.2% |
19% |
13.31 |
2.1 |
10.9 |
Industry Mean |
|
|
-19% |
16% |
14.26 |
45.3 |
10.5 |
| S&P 500 |
|
|
23% |
11% |
13.71
| 1.9 |
|
|
|
|
|
|
|
|
|
USNA (USANA HLTH SCI) |
$459.00 |
$36.55 |
52.9% |
18% |
14.42 |
1.2 |
13.4 |
MRX (MEDICIS PHARM-A) |
$639.00 |
$110.99 |
18.6% |
11% |
11.05 |
2.1 |
9.6 |
BVF (BIOVAIL CORP) |
$867.00 |
$134.30 |
21.3% |
7% |
15.97 |
2.7 |
5.8 |
CF is operating cash flow plus after-tax interest expense. |
|
| Discussion of Relative Valuation | | No comments yet. Be the first | | |
|
|
| | |
Created by: WikiMigrationBot.
Last Modification: Thursday 03 of June, 2010 06:30:11 CDT by WikiMigrationBot.
|
